Research programme: small molecule therapeutics - Cardax Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Cardax Pharmaceuticals

Alternative Names: CDX-303; CDX-505; OcuXan; Prostatix

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardax Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Age-related macular degeneration; Liver disorders; Prostate cancer

Most Recent Events

  • 25 Apr 2018 Cardax Pharmaceutica has patent pending for small molecule therapeutics in Europe, Canada and Brazil
  • 25 Apr 2018 Cardax Pharmaceutica has patent protection for small molecule therapeutics in Europe, China, India, Japan and Hong Kong
  • 31 Mar 2017 Early research in Liver disorders in USA, before March 2017 (Cardax Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top